ED Drugs Linked to Increased Melanoma Risk

Larry Hand

April 10, 2014

Use of sildenafil (Viagra, Pfizer) is associated with an increased risk for melanoma, according to an article published online April 7 in JAMA Internal Medicine.

Researchers caution, however, that their study does not provide sufficient evidence to change clinical recommendations for erectile dysfunction (ED) treatments.

Wen-Qing Li, PhD, from the Department of Dermatology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, and colleagues conducted a prospective cohort study of participants in the Health Professionals' Follow-up Study (HPFS) between 2000 and 2010. Their analysis included data on 25,848 men.

They initiated their study after prior studies indicated that phosphodiesterase 5A (PDG5A) inhibitors, including sildenafil, may promote melanin synthesis, which itself may promote melanoma development. In addition, published research has linked sildenafil use and other PDG5A inhibitors to promotion of melanoma cell invasion, particularly in individuals who carry a mutation in the BRAF gene.

The current analysis did not include other PDG5A inhibitors, such as tadalafil (Cialis, Eli Lilly) and vardenafil (Levitra, GlaxoSmithKline), because they were not approved when the cohort study began.

HPFS participants were asked in the 2000 biennial survey whether they had been treated or were being treated for ED; 1378 of the 25,848 participants (5.3%) reported taking sildenafil in the previous 3 months and 1618 (6.3%) reported ever taking sildenafil. These men were more likely to be older than the entire HPFS cohort (66.1 years vs 64.8 years; P < 0.001). They were also more likely to be obese and to have a history of severe or blistering sunburns but less sun exposure in adulthood.

HPFS participants had been reporting diagnoses of melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC) in biennial surveys since 1986. During follow-up in 2000 through 2010, the researchers found 142 cases of melanoma, 580 cases of SCC, and 3030 cases of BCC.

Almost Twice the Risk

Recent sildenafil users were significantly more likely to be diagnosed with invasive melanoma than nonusers in an analysis adjusted for multiple variables (hazard ratio [HR], 1.84; 95% confidence interval [CI], 1.04 - 3.22). Those who had ever used sildenafil also carried greater risk for melanoma (HR, 1.92; 95% CI, 1.14 - 3.22). However, neither group of sildenafil users showed an elevated risk for SCC or BCC compared with nonusers.

The researchers adjusted their analyses for a variety of factors, including age, body mass index, tobacco use, physical activity, and childhood reaction to sun, plus melanoma risk factors, such as mole count, hair color, and family history.

The age-standardized absolute risk associated with sildenafil use came to 81 cases per 100,000 person-years (216.4/100,000 for users and 135.4/100,000 nonusers).

Although the researchers did not include other PDG5A inhibitors in their study, they note, "The observed association between sildenafil use and melanoma might be partly attributed to the later use of vardenafil and tadalafil among recent sildenafil users. A longer clearance time of other PDE5A inhibitors could have augmented the observed HR for sildenafil."

They conclude, "Our results should be interpreted cautiously and are insufficient to alter current clinical recommendations. Nevertheless, our data provide epidemiological evidence on possible skin adverse effects of PDE5A inhibitors and support continued investigation of this relationship."

A Chance for Primary Care

In an Invited Commentary, June K. Robinson, MD, editor of JAMA Dermatology and from the Department of Dermatology at Northwestern University Feinberg School of Medicine, Chicago, Illinois, writes that primary care physicians are in a position to screen for melanoma in older men, especially when prescribing sildenafil.

"With the proportion of Americans who are 65 years or older projected to increase from 12% in 2005 to 20% by 2030, more patients cared for by primary care physicians will have melanomas," she writes. "The mental note to screen the man requesting sildenafil could prompt the physician to check the patient's face, bald scalp, ears, and neck."

She continues, "It is appropriate to perform a biopsy if the physician sees a pigmented lesion with 3 of these features: a diameter of 6 mm or more, an asymmetric shape, irregular borders, and a variety of colors, ranging from tans and browns to black."

Early detection may make melanoma a curable disease, she writes.

The Health Professionals' Follow-up Study is partially supported the National Institutes of Health. The authors and the commentator have disclosed no relevant financial relationships.

JAMA Intern Med. Published online April 7, 2014. Abstract  Invited Commentary


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.